CARNEYS POINT, NJ--(Marketwired - April 29, 2015) - CannaPharmaRx, Inc. (OTCQB: CPMD), an early stage pharmaceutical company whose purpose is to advance cannabinoid research and discovery (the "Company"), announced today that they will be attending the annual Armada Specialty Pharmacy Summit, which is scheduled from May 4-8, 2015 at the Wynn Hotel in Las Vegas.
This annual event is one of the largest conferences for the specialty pharmacy industry. It includes thousands of attendees from pharmacy providers, pharma/biotech manufacturers, payers and many other specialty pharmacy stakeholder organizations. This conference provides an unmatched opportunity for all attendees from around the nation to learn about specialty pharmacy while connecting and networking with leading industry executives, professionals and senior decision-makers within the specialty pharmacy channel.
"As CannaPharmaRx moves forward into this marketplace, our specialty and compounding pharmacy acquisition strategy will allow us to produce revenue and EBITDA, thereby reducing cash burn, as well mitigate risk in our cannabinoid drug development and commercial manufacturing strategies and support critical patient needs in the current healthcare environment. With the expected development of our own proprietary products, our ability to move quickly into the healthcare arena will likely accelerate based on the infrastructure we plan to build with payers and pharmaceutical manufacturers. Our efforts at Armada will focus on building these relationships," says Jim Smeeding R.Ph., MBA, the Company's Executive Vice President of Professional Services and a member of its Board of Directors.
About CannaPharmaRx, Inc.
CannaPharmaRx, Inc. is an early-stage pharmaceutical company whose purpose is to advance cannabinoid research and discovery using proprietary formulation and drug delivery technology currently in development. Cannabinoids are a class of chemicals that, once ingested, are active in humans and animals through the "endocannabinoid system" -- one of the most widely expressed system of receptors in the human body. CannaPharmaRx is currently focused on targeting disease states where its delivery systems can have optimal impact with therapeutic differentiation among alternative cannabinoid therapies, including: neurological disorders, oncology, infectious disease, pain management, inflammatory disease, gastrointestinal disorders and ophthalmology. For more information, please visit www.CannaPharmaRx.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated," and "intend" among others. These forward-looking statements are based on CannaPharmaRx's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to: our ability to satisfy the closing conditions to the proposed merger, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical products under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that the merger or other matters discussed in this press release will be completed or successful. CannaPharmaRx does not undertake any obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in CannaPharmaRx's Annual Report on Form 10-K for the year ended December 31, 2014 and other periodic reports filed with the Securities and Exchange Commission.
Investor Relations for Viridian Capital & Research, LLC:
Michael Swartz, Analyst
212-333-0257
mswartz@viridiancr.com
Investor Relations for CannaPharmaRx, Inc.:
Bridamary Rosario
856-376-0500
bbrosario@cannapharmarx.com
